Somewhat Positive Media Coverage Somewhat Unlikely to Affect Geron Corporation (GERN) Stock Price

News coverage about Geron Corporation (NASDAQ:GERN) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Geron Corporation earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.8916237765611 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

Shares of Geron Corporation (NASDAQ GERN) traded down $0.15 during midday trading on Wednesday, reaching $1.80. 5,122,800 shares of the company’s stock were exchanged, compared to its average volume of 1,433,169. Geron Corporation has a 1 year low of $1.74 and a 1 year high of $3.15.

Geron Corporation (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.40 million. Geron Corporation had a negative return on equity of 25.14% and a negative net margin of 2,992.67%. The business’s revenue for the quarter was down 96.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.02) earnings per share. equities analysts expect that Geron Corporation will post -0.17 EPS for the current fiscal year.

A number of equities analysts recently commented on GERN shares. Zacks Investment Research downgraded Geron Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Stifel Nicolaus reissued a “hold” rating and issued a $2.50 target price on shares of Geron Corporation in a report on Friday, November 3rd. BidaskClub cut shares of Geron Corporation from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Geron Corporation in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Geron Corporation presently has an average rating of “Hold” and an average price target of $3.75.

WARNING: This piece of content was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Insider Buying and Selling by Quarter for Geron Corporation (NASDAQ:GERN)

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with's FREE daily email newsletter.

Leave a Reply